The Leucine-Rich α2-Glycoprotein-1 Levels in Patients with Multiple Myeloma.

Oncol Res Treat

Department of Medical Biochemistry, Faculty of Medicine, Hatay Mustafa Kemal University, Antakya, Turkey.

Published: October 2023

AI Article Synopsis

  • Angiogenesis plays a crucial role in multiple myeloma (MM) development and treatment, with LRG1 being a key protein involved in this process.
  • The study involved 112 MM patients categorized into four groups (newly diagnosed, relapsed refractory, in remission, and control) to analyze LRG1 and other relevant biomarker levels via blood tests.
  • Results showed that newly diagnosed MM patients had significantly higher levels of LRG1 and associated proteins compared to the other groups, alongside strong correlations with various clinical indicators related to disease severity.

Article Abstract

Introduction: Angiogenesis is considered important in the pathogenesis of multiple myeloma (MM), as well as in the targeted treatment of the disease. Leucine-rich α2-glycoprotein 1 (LRG1) is a protein that participates in angiogenesis and its effect on solid organ tumors has been investigated recently. This study aimed to investigate the relationship between MM and LRG1.

Methods: The MM patients who admitted to Hatay Mustafa Kemal University Hematology Clinic between September 2021 and October 2022 were included in the study. The study consists of a total of 4 groups: newly diagnosed MM (NDMM), relapsed refractory MM (RRMM), MM in remission (Rem-MM), and control group. Demographic data were retrieved from hospital records. Blood samples of our study groups were centrifuged at 1,500 × g for 10 min and serum was collected. LRG1, IL-6, IL-8, TGF-β1, HIF-1α, FGF-2, and VEGF levels were analyzed in all groups by ELISA method, and statistical analysis was performed.

Results: A total of 112 individuals, including NDMM (n: 27), RRMM (n: 18), Rem-MM (n: 42), and control group (n: 25), were enrolled in the study. Based on the analyses, the NDMM group exhibited significantly elevated levels of LRG1 (p < 0.001), TGF-1 (p < 0.001), and HIF-1α (p = 0.046, p < 0.001, and p = 0.003 compared to the RRMM, Rem-MM, and control groups, respectively) compared to the other groups. LRG1 levels were positively correlated with creatinine (r: 0.363, p = 0.001), calcium (r: 0.344, p = 0.001), total protein (r: 0.473, p < 0.001), erythrocyte sedimentation rate (r: 0.547, p < 0.001), lactate dehydrogenase (r: 0.321, p = 0.003), beta-2-microglobulin (r: 0.312, p = 0.017), IL-6 (r: 0.478, p < 0.001), IL-8 (r: 0.240, p = 0.03), TGF-β1 (r: 0.521, p < 0.001), and HIF-1α (r: 0.321, p = 0.003) levels and were negatively correlated with hemoglobin (r: -0.512, p < 0.001) and albumin (r: -0.549, p < 0.001) levels. Receiver operating characteristics (ROC) analysis revealed the association of LRG1 with the highest AUC value of 0.959 (95% CI: 0.904-1, p < 0.001) and the optimal cut-off value of 534.95 ng/mL (sensitivity: 93% and specificity: 99%) in the NDMM group compared to the control group.

Conclusion: In this study, providing data for the first time on LRG1 levels in the setting of MM. LRG1 levels were found to be significantly higher in NDMM patients and in our study discriminate this patient population from RRMM, Rem-MM, and normal controls. Therefore, LRG1 seems to a potential biomarker that should be evaluated in future studies addressing the diagnosis, staging, follow-up, prognosis, and treatment target of MM.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000532042DOI Listing

Publication Analysis

Top Keywords

rem-mm control
12
rrmm rem-mm
12
0001
12
lrg1 levels
12
levels
8
multiple myeloma
8
lrg1
8
control group
8
ndmm group
8
0001 hif-1α
8

Similar Publications

Multiple myeloma (MM) is a bone marrow malignancy characterized by plasma cell proliferation. It was aimed to investigate pentraxin 3 (PTX3) levels, oxidative/antioxidative status, and their correlation in MM. In the study, four groups were established, including newly diagnosed MM (NDMM), MM in remission (Rem-MM), relapsed/refractory MM (RRMM) patients, and a healthy control group.

View Article and Find Full Text PDF

The Leucine-Rich α2-Glycoprotein-1 Levels in Patients with Multiple Myeloma.

Oncol Res Treat

October 2023

Department of Medical Biochemistry, Faculty of Medicine, Hatay Mustafa Kemal University, Antakya, Turkey.

Article Synopsis
  • Angiogenesis plays a crucial role in multiple myeloma (MM) development and treatment, with LRG1 being a key protein involved in this process.
  • The study involved 112 MM patients categorized into four groups (newly diagnosed, relapsed refractory, in remission, and control) to analyze LRG1 and other relevant biomarker levels via blood tests.
  • Results showed that newly diagnosed MM patients had significantly higher levels of LRG1 and associated proteins compared to the other groups, alongside strong correlations with various clinical indicators related to disease severity.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!